Venous thromboembolism, though rare in the community, is a major cause of death among hospitalized patients. It is estimated to cause 100,000 deaths per year and to contribute to mortality in another ...

Bristol-Myers Squibb and Pfizer announced that the FDA has accepted for review a supplemental New Drug Application (sNDA) for Eliquis (apixaban), for prophylaxis of deep vein thrombosis (DVT), which ...

Functional impairment (FI) after hematopoietic cell transplantation (HCT) and impact on quality of life (QOL). Bupropion for hot flashes control in breast cancer survivors: A prospective, double-blind ...

ORLANDO, Fla. — Patients who underwent hip fracture surgery and were prescribed deep vein thrombosis prophylaxis for 28 days or more had a 67% lower chance of death and significantly lower ...

Ridgefield, CT, April 6, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) filed a supplemental New Drug Application (sNDA) for ...

Rivaroxaban (Xarelto; Bayer/Janssen) has gained an additional indication, this time for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized patients at increased risk for ...

antithrombin III [human] Thrombate III inj Hereditary antithrombin III (AT-III) deficiency in surgical or obstetrical procedures and thromboembolism Infuse over 10–20mins. Dose (units required) = ...

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long ...

The post-operative risk period for venous thromboembolism is still unknown and indications for post-discharge prophylaxis are controversial. Detectable thrombus formation after hip arthroplasty is ...

LUND, Sweden & LEUVEN, Belgium--(BUSINESS WIRE)-- BioInvent International AB (OMXS:BINV) and ThromboGenics NV (Euronext Brussels:THR) announce today positive results from their Phase II trial of ...